International Journal of Hematology

DOI: 10.1007/s12185-015-1785-1 Pages: 452-466

State-of-the-art acute and chronic GVHD treatment

1. University of Alabama at Birmingham (UAB), Division of Hematology and Oncology

2. University of Alabama at Birmingham (UAB), Blood and Marrow Transplantation and Cell Therapy Program

Correspondence to:
Shin Mineishi
Tel: 205-975-0837



Graft-versus-host disease (GVHD) remains as the major obstacle for successful hematopoietic stem cell transplant (HSCT). Roughly half of the patients undergoing HSCT develop GVHD which requires treatment, and above 10 % of the patient may die because of it. However, GVHD presents with anti-tumor activity, called graft-versus-tumor (GVT) effect, and it carries significant anti-tumor activity, thus suppressing GVHD completely may increase the relapse of original disease. Thus, it is important to control GVHD to the appropriate level.

This article is freely available, click here to access the full text/PDF

Share the Knowledge